Overall survival (upper part) and time to disease progression (lower part) of patients with CML treated with IFN-α2b or hydroxyurea only, calculated from date of randomization. Curves are based on the intention to treat, regardless of any protocol violation or cause of death. Data on those patients that underwent BMT during chronic phase were censored as of the date of transplantation.